Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
FLT3-ITD mutation
i
Other names:
FLT3, Fms Related Tyrosine Kinase 3, Receptor-Type Tyrosine-Protein Kinase FLT3, Stem Cell Tyrosine Kinase 1, Fms-Like Tyrosine Kinase 3, CD135, FLK-2, STK1, Growth Factor Receptor Tyrosine Kinase Type III, Fetal Liver Kinase 2
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
2322
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
›
Related tests:
LeukoStrat® CDx FLT3 Mutation Assay (6)
LeukoStrat® CDx FLT3 Mutation Assay (6)
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
FLT3-ITD mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation
Acute Myelogenous Leukemia
quizartinib
Sensitive: A1 - Approval
quizartinib
Sensitive
:
A1
quizartinib
Sensitive: A1 - Approval
quizartinib
Sensitive
:
A1
FLT3-ITD mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation
Acute Myelogenous Leukemia
midostaurin
Sensitive: A2 - Guideline
midostaurin
Sensitive
:
A2
midostaurin
Sensitive: A2 - Guideline
midostaurin
Sensitive
:
A2
FLT3-ITD mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation
Acute Myelogenous Leukemia
gilteritinib
Sensitive: A2 - Guideline
gilteritinib
Sensitive
:
A2
gilteritinib
Sensitive: A2 - Guideline
gilteritinib
Sensitive
:
A2
FLT3-ITD mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation
Acute Myelogenous Leukemia
sorafenib
Sensitive: A2 - Guideline
sorafenib
Sensitive
:
A2
sorafenib
Sensitive: A2 - Guideline
sorafenib
Sensitive
:
A2
FLT3-ITD mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation
Acute Myelogenous Leukemia
cytarabine
Resistant: B - Late Trials
cytarabine
Resistant
:
B
cytarabine
Resistant: B - Late Trials
cytarabine
Resistant
:
B
FLT3-ITD mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation
Acute Myelogenous Leukemia
venetoclax + azacitidine
Sensitive: B - Late Trials
venetoclax + azacitidine
Sensitive
:
B
venetoclax + azacitidine
Sensitive: B - Late Trials
venetoclax + azacitidine
Sensitive
:
B
FLT3-ITD mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation
Acute Myelogenous Leukemia
venetoclax
Sensitive: C2 – Inclusion Criteria
venetoclax
Sensitive
:
C2
venetoclax
Sensitive: C2 – Inclusion Criteria
venetoclax
Sensitive
:
C2
FLT3-ITD mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation
Acute Myelogenous Leukemia
ponatinib
Sensitive: C2 – Inclusion Criteria
ponatinib
Sensitive
:
C2
ponatinib
Sensitive: C2 – Inclusion Criteria
ponatinib
Sensitive
:
C2
FLT3-ITD mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation
Acute Myelogenous Leukemia
TP-0903
Sensitive: C2 – Inclusion Criteria
TP-0903
Sensitive
:
C2
TP-0903
Sensitive: C2 – Inclusion Criteria
TP-0903
Sensitive
:
C2
FLT3-ITD mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation
Acute Myelogenous Leukemia
PHI-101
Sensitive: C2 – Inclusion Criteria
PHI-101
Sensitive
:
C2
PHI-101
Sensitive: C2 – Inclusion Criteria
PHI-101
Sensitive
:
C2
FLT3-ITD mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation
Acute Myelogenous Leukemia
pexidartinib
Sensitive: C2 – Inclusion Criteria
pexidartinib
Sensitive
:
C2
pexidartinib
Sensitive: C2 – Inclusion Criteria
pexidartinib
Sensitive
:
C2
FLT3-ITD mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation
Acute Myelogenous Leukemia
quizartinib + RAIN-32
Sensitive: C2 – Inclusion Criteria
quizartinib + RAIN-32
Sensitive
:
C2
quizartinib + RAIN-32
Sensitive: C2 – Inclusion Criteria
quizartinib + RAIN-32
Sensitive
:
C2
FLT3-ITD mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation
Acute Myelogenous Leukemia
venetoclax + quizartinib
Sensitive: C2 – Inclusion Criteria
venetoclax + quizartinib
Sensitive
:
C2
venetoclax + quizartinib
Sensitive: C2 – Inclusion Criteria
venetoclax + quizartinib
Sensitive
:
C2
FLT3-ITD mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation
Acute Myelogenous Leukemia
HEC73543
Sensitive: C2 – Inclusion Criteria
HEC73543
Sensitive
:
C2
HEC73543
Sensitive: C2 – Inclusion Criteria
HEC73543
Sensitive
:
C2
FLT3-ITD mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation
Acute Myelogenous Leukemia
ARO-002
Sensitive: C2 – Inclusion Criteria
ARO-002
Sensitive
:
C2
ARO-002
Sensitive: C2 – Inclusion Criteria
ARO-002
Sensitive
:
C2
FLT3-ITD mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation
Acute Myelogenous Leukemia
gilteritinib + quizartinib + fingolimod
Sensitive: C3 – Early Trials
gilteritinib + quizartinib + fingolimod
Sensitive
:
C3
gilteritinib + quizartinib + fingolimod
Sensitive: C3 – Early Trials
gilteritinib + quizartinib + fingolimod
Sensitive
:
C3
FLT3-ITD mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation
Acute Myelogenous Leukemia
FLT3 inhibitor
Sensitive: C3 – Early Trials
FLT3 inhibitor
Sensitive
:
C3
FLT3 inhibitor
Sensitive: C3 – Early Trials
FLT3 inhibitor
Sensitive
:
C3
FLT3-ITD mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation
Acute Myelogenous Leukemia
cytarabine + idarubicin
Resistant: C3 – Early Trials
cytarabine + idarubicin
Resistant
:
C3
cytarabine + idarubicin
Resistant: C3 – Early Trials
cytarabine + idarubicin
Resistant
:
C3
FLT3-ITD mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation
Acute Myelogenous Leukemia
venetoclax + gilteritinib
Sensitive: C3 – Early Trials
venetoclax + gilteritinib
Sensitive
:
C3
venetoclax + gilteritinib
Sensitive: C3 – Early Trials
venetoclax + gilteritinib
Sensitive
:
C3
FLT3-ITD mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation
Acute Myelogenous Leukemia
gemtuzumab ozogamicin
Sensitive: C3 – Early Trials
gemtuzumab ozogamicin
Sensitive
:
C3
gemtuzumab ozogamicin
Sensitive: C3 – Early Trials
gemtuzumab ozogamicin
Sensitive
:
C3
FLT3-ITD mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation
Acute Myelogenous Leukemia
selumetinib
Resistant: C3 – Early Trials
selumetinib
Resistant
:
C3
selumetinib
Resistant: C3 – Early Trials
selumetinib
Resistant
:
C3
FLT3-ITD mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation
Acute Myelogenous Leukemia
venetoclax + ruxolitinib
Sensitive: C3 – Early Trials
venetoclax + ruxolitinib
Sensitive
:
C3
venetoclax + ruxolitinib
Sensitive: C3 – Early Trials
venetoclax + ruxolitinib
Sensitive
:
C3
FLT3-ITD mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation
Acute Myelogenous Leukemia
sorafenib + gilteritinib
Sensitive: C3 – Early Trials
sorafenib + gilteritinib
Sensitive
:
C3
sorafenib + gilteritinib
Sensitive: C3 – Early Trials
sorafenib + gilteritinib
Sensitive
:
C3
FLT3-ITD mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation
Acute Myelogenous Leukemia
FF-10101
Sensitive: C3 – Early Trials
FF-10101
Sensitive
:
C3
FF-10101
Sensitive: C3 – Early Trials
FF-10101
Sensitive
:
C3
FLT3-ITD mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation
Acute Myelogenous Leukemia
DCAG
Sensitive: C3 – Early Trials
DCAG
Sensitive
:
C3
DCAG
Sensitive: C3 – Early Trials
DCAG
Sensitive
:
C3
FLT3-ITD mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation
Acute Myelogenous Leukemia
decitabine
Sensitive: C3 – Early Trials
decitabine
Sensitive
:
C3
decitabine
Sensitive: C3 – Early Trials
decitabine
Sensitive
:
C3
FLT3-ITD mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation
Acute Myelogenous Leukemia
midostaurin + gemtuzumab ozogamicin
Sensitive: C3 – Early Trials
midostaurin + gemtuzumab ozogamicin
Sensitive
:
C3
midostaurin + gemtuzumab ozogamicin
Sensitive: C3 – Early Trials
midostaurin + gemtuzumab ozogamicin
Sensitive
:
C3
FLT3-ITD mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation
Acute Myelogenous Leukemia
DA
Sensitive: C4 – Case Studies
DA
Sensitive
:
C4
DA
Sensitive: C4 – Case Studies
DA
Sensitive
:
C4
FLT3-ITD mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation
Acute Myelogenous Leukemia
SGN-CD33A
Sensitive: D – Preclinical
SGN-CD33A
Sensitive
:
D
SGN-CD33A
Sensitive: D – Preclinical
SGN-CD33A
Sensitive
:
D
FLT3-ITD mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation
Acute Myelogenous Leukemia
bortezomib + verteporfin
Sensitive: D – Preclinical
bortezomib + verteporfin
Sensitive
:
D
bortezomib + verteporfin
Sensitive: D – Preclinical
bortezomib + verteporfin
Sensitive
:
D
FLT3-ITD mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation
Acute Myelogenous Leukemia
bortezomib
Sensitive: D – Preclinical
bortezomib
Sensitive
:
D
bortezomib
Sensitive: D – Preclinical
bortezomib
Sensitive
:
D
FLT3-ITD mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation
Acute Myelogenous Leukemia
Max-40279
Sensitive: D – Preclinical
Max-40279
Sensitive
:
D
Max-40279
Sensitive: D – Preclinical
Max-40279
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login